Joshua Resnick - May 26, 2023 Form 4 Insider Report for Vor Biopharma Inc. (VOR)

Role
Director
Signature
/s/ Katie Kazem, Attorney-in-Fact
Stock symbol
VOR
Transactions as of
May 26, 2023
Transactions value $
$0
Form type
4
Date filed
6/2/2023, 04:39 PM
Previous filing
Jun 22, 2022
Next filing
Jun 8, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VOR Stock Option (right to buy) Award $0 +30K $0.00 30K May 26, 2023 Common Stock 30K $4.79 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) May 26, 2024 or (ii) the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.
F2 Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney